Crisp 2012.

Study characteristics
Methods	Parallel, participants received IV opioids on postoperative day 0 only, with follow‐up to 14 days
Participants	PCA 32, control 27 Vaginal reconstructive surgery
Interventions	PCA: hydromorphone. Bolus/lockout/4 h limit: 0.2 mg/8 min/5 mg Control: IV hydromorphone 0.5 mg every 2 h with option to decline
Outcomes	Primary: pain intensity and satisfaction with pain control Secondary: opioid use, side effects
Source of funding	Not mentioned
Notes	QS = 3 (R = 2, DB = 0, W = 1)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated (nQuery Advisor) randomization table
Allocation concealment (selection bias)	Low risk	Sequentially numbered, opaque, sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned – assume no blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low numbers of dropouts, not related to interventions
Selective reporting (reporting bias)	Low risk	Trial registered on clinicaltrials.gov NCT01442818. No results posted, but amount of opioid used not listed as secondary outcome. Primary outcomes same as in manuscript
Other bias	Unclear risk	Small sample size